perpetuity. It is made available under a CC-BY-ND 4.0 International license .

# Evaluating the effects of second-dose vaccine-delay policies in European countries: A simulation study based on data from Greece

P. Barmpounakis<sup>1\*</sup> N. Demiris<sup>1</sup> I. Kontoyiannis<sup>2</sup> G. Pavlakis<sup>3</sup> V. Sypsa<sup>4</sup>

<sup>1</sup> Department of Statistics, Athens University of Economics and Business, Athens, Greece <sup>2</sup> <u>Department of Pure Mathematics and Mathematical Statistics</u>, University of Cambridge, Cambridge, United Kingdom

<sup>3</sup> Human Retrovirus Section, National Cancer Institute, Frederick, Maryland, United States of America

<sup>4</sup> Dept. of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece

\*Corresponding author

E-mail: <u>barmpounakis@aueb.gr</u> (PB)

# Abstract

The results of a simulation-based evaluation of several policies for vaccine rollout are reported, particularly focusing on the effects of delaying the second dose of two-dose vaccines. In the presence of limited vaccine supply, the specific policy choice is a pressing issue for several countries worldwide, and the adopted course of action will affect the extension or easing of non-pharmaceutical interventions in the next months. We employ a suitably generalised, age-structure, stochastic SEIR (Susceptible  $\rightarrow$  Exposed  $\rightarrow$  Infectious  $\rightarrow$  Removed) epidemic model that can accommodate quantitative descriptions of the major effects resulting from distinct vaccination strategies. The different rates of social contacts among distinct agegroups (as well as some other model parameters) are informed by a recent survey conducted in Greece, but the conclusions are much more widely applicable. The results are summarised and evaluated in terms of the total number of deaths and infections as well as life years lost. The optimal strategy is found to be one based on fully vaccinating the elderly/at risk as guickly as possible, while extending the time-interval between the two vaccine doses to 12 weeks for all individuals below 75 years old, in agreement with epidemic theory which suggests targeting a combination of susceptibility and infectivity. This policy, which is similar to the approaches adopted in the UK and in Canada, is found to be effective in reducing deaths and life years lost in the period while vaccination is still being carried out.

# Introduction

Since December 2019, COVID-19 has presented a global threat to public health and to the worldwide economy, and it will likely continue to disrupt livelihoods until a high percentage of the population is vaccinated. High vaccination rates will be necessary to reach herd immunity in a short period of time. Standard theory [1] suggests that a proportion approximately equal to  $1-1/R_0$  of the population will have to become immune (either through vaccination or previous infection) in order to effectively suppress disease transmission, where  $R_0$  is the virus' basic reproduction number. The actual vaccination coverage required is likely to vary due to population heterogeneity, previous levels of spread of infection, and other local factors. In addition, the exact value of  $R_0$  for SARS-CoV-2 under "normal" conditions remains quite uncertain since there has been very little disease spread without some mitigation effort due to non-pharmaceutical interventions, and also due to the appearance of new variants. Therefore, constrained scenarios are likely to give a realistic estimate of the effect of distinct vaccination policies and this

NOTE ARIS PRESENT SEARCH SEARCH Rather South Back South

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Assuming a vaccination coverage between 60%-80% of the population, 3.1-4.1 billion people worldwide will need to be vaccinated [2]. With several seemingly highly efficacious vaccines available (efficacy estimated at 94.1%, 95% and 62% for Moderna, Pfizer-BioNTech and Oxford-AstraZeneca respectively) against COVID-19 disease [3-5] it appears that a return to near-normality for society and for the economy may soon be possible. Unfortunately, limited supply is currently an impediment to achieving high vaccination coverage rapidly [6].

In addition to social distancing [7] and mass testing [8], the fair allocation of scarce medical interventions such as vaccines presents ethical challenges as there are different allocation principles - treating people equally, favouring the worst-off, maximising total benefits, and promoting and rewarding social usefulness - and no single principle can address all morally relevant considerations [9,10]. Modelling studies broadly agree that, when vaccine supply is limited, prioritising the elderly is a necessary strategy to reduce COVID-19 mortality, whereas the prioritisation of younger individuals would have an impact on reducing transmission [11,12]. This agrees with epidemic theory [1] which suggests that the focus for disease control should be based on a combination of targeting susceptibility and infectivity. Therefore, assuming very scarce resources, it makes sense to focus on the most vulnerable individuals in the population. On the other extreme is the presence of nearly unlimited vaccine supply, whence aiming for achieving herd immunity is straightforward. In this work we focus on the intermediate problem which many European countries are currently facing, and prioritisation of vaccines is of the essence.

Due to supply constraints, it was decided in the UK and Canada to delay the administration of the second dose of all vaccines, based on the rationale that SARS-CoV-2 vaccination offers considerable protection after the first dose and that more people could benefit [13,14]. Although this approach seems appealing, the impact of delaying the second dose is not straightforward as it depends on several parameters such as the efficacy of the first dose in time, the levels of transmission in the population, vaccination rollout, and the vaccine profile (reduction in symptoms or in symptoms and infection) [15-17]. Country-specific information on the age-distribution of the population and social mixing patterns are also necessary to obtain realistic estimates.

The main contribution of this work is the evaluation of different vaccination strategies and their potential benefits, primarily based on data from Greece, a typical country of the EU area in terms of vaccine availability and administration, with a population of around 10.8 million people. The current strategy (strategy I) is to give the second vaccine dose three weeks after the first for the Pfizer vaccine, which currently consists of the largest portion of the available vaccines in the EU. We consider an alternative policy (strategy II) where, after the vaccination of medical personnel and those over 75, a portion of the available vaccines is distributed with a three-month time interval between the two doses. The prioritization of the medical personnel and those over 75 years old is kept constant for every strategy. Our methodology examines scenarios where the two different vaccination schedules are combined in different proportions, allowing us to explore the optimal portion of the population that should be vaccinated using the extended three-month time interval between the two doses. This is something that has not been extensively explored in the literature, since earlier studies primarily focus on finding the optimal timing of the second dose, considering that the entire population will follow the same schedule [18-20]. Extending the time interval between doses to three months aims for faster partial coverage of economically active individuals, therefore offering indirect protection to a larger proportion of the population and ultimately for potentially reducing the pandemic cost to public health and the society. This is implicitly informed by aiming for a combined effect of reducing

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

susceptibility and infectivity in the population. Different scenarios of vaccine availability and transmission rates are considered, as well as different scenarios for the acquired immunity after the first dose for strategy II. We assess our results through simulation of an age-structured stochastic SEIR (Susceptible  $\rightarrow$  Exposed  $\rightarrow$  Infectious  $\rightarrow$  Removed) epidemic model, suitably modified to account for the number of vaccinated individuals with different protocols.

We opted for a stochastic model because the most effective way to describe the spread of a disease is stochastic, based on the specification of the probability of disease transmission between two individuals. One may incorporate additional sources of stochasticity in the length of latent and infectious periods, but it is well known that such uncertainty is immaterial in terms of its effect on the outcome of an epidemic, particularly in a large population setting such as country-level studies; see for example [21]. Since the writing of this paper, related modelling techniques using deterministic dynamics have been proposed, that use optimization techniques to infer the model parameters and find the optimal dosing schedule [18,19]. An extension of a discrete-time, deterministic susceptible-infected-recovered model was used in [22] to plan the scheduling of first and second vaccine doses, with the underlying objective of the optimization problem being the concurrent minimization of both the healthcare impact of the epidemic and of the socio-economic impact due to the implementation of non-pharmaceutical interventions. A similarly extended SEIR model was also used to measure (through simulation) whether the effect of a standard vaccination schedule for different uptake scenarios is enough to stop the epidemic without the need of non-pharmaceutical interventions [20].

# **Materials and methods**

## The multitype S(V)EIR model and simulation description

The model used for the simulation of different vaccination strategies is an agestructured stochastic SEIR model that accounts for different vaccinated populations and vaccinated states, termed S(V)EIR henceforth. A schematic representation of the model is given in Fig 1.



Fig 1. Schematic representation of the S(V)EIR epidemic model for the baseline scenario of immunity waning.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

In order to evaluate the effects of different vaccination strategies, this model also accounts for the age composition of the population, the social mixing rates of different age groups, the intention to get vaccinated, as well as the different risk of death of each age group. The code for simulating the model is publicly available at: <u>https://github.com/pbarmpounakis/Evaluating-the-effects-of-vaccine-rollout-policies-in-European-countries-A-simulation-study</u>.

A detailed description of the model follows, while a summary of the quantitative assumptions made is given in S1 Table in Supporting information B.

# States and vaccination effect assumptions

Two groups are considered for the vaccinated people representing the two distinct vaccination categories. In vaccination group 1, individuals receive the 2<sup>nd</sup> dose of the vaccine after 3 months while in vaccination group 2 it is given after 3 weeks. In both vaccination groups, individuals who received the 1<sup>st</sup> dose of the vaccine move to states V11 and V21 respectively and remain fully susceptible. Two weeks after the 1<sup>st</sup> dose individuals from both vaccination groups move to the second stage (V12, V22 respectively), whence immunity jumps to 68% [5]. Individuals from vaccination group 2 remain at V22 for another 7 days when they take their  $2^{nd}$  dose and move to state 3 (V23) with their immunity jumping at 95% after two weeks. Individuals from vaccination group 1 take their second dose 78 days after entering V12 and then move to state V15 with their immunity changing based on different waning immunity scenarios described below. The stages V13, V14 and V15 account for the drop of the immunity due to waning vaccine efficacy 26, 52 and 78 days after the first dose, respectively. They move to V16 14 days later when their immunity jumps to 95%, pertaining to the reported efficacy of the mRNAbased vaccines which are mostly used in European countries [3-5]

# Transmission model assumptions

New infections from each state s and age group i follow a Binomial distribution with size given by the number of people in state *s* and age group *i*, and infection probability  $(1 - immunity_s) * (1 - e^{\sum_{j=1}^{n} groups}(\lambda_{ij}*I_j/N_j))$ , where *immunitys* is the level of immunity at stage s,  $I_i$  is the number of infectious individuals at age group j,  $N_i$  is the total number of individuals at age group j,  $\lambda_{ij}$  is the i, j entry in the transmission matrix  $\lambda$ , and *n* groups is the total number of different age groups. Following infection, individuals of age group *i* follow the Exposed (E<sub>i</sub>)  $\rightarrow$  Infectious (I<sub>i</sub>)  $\rightarrow$ Removed ( $R_i$ ) path with a constant exposure time of 2 days, based on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms [26-28]. The infectious period is also assumed constant and set at 6 days for non-vaccinated individuals [29-31] and 2 or 3 days for vaccinated ones, depending upon the scenario of immunity waning and vaccine efficacy in reducing the infectious period [32,33]. The choices of these values are conservative assuming that in reality people experiencing influenza-like symptoms will get tested and self-isolate, resulting in lower effective infectious period. The total number of deaths is computed by multiplying the number in  $R_i$  with the infection fatality ratio (IFR) of each age group for the unvaccinated individuals as it was reported by [34] and with [IFR x 5%] for those vaccinated [35].

# Different scenarios for *R*<sub>t</sub> and immunity

Transmission levels corresponding to a constant effective reproduction number  $R_t=1.2$  and  $R_t=1.4$  are considered along with various levels of immunity at each stage of vaccination for group 1. These choices of  $R_t$  suggest moderate transmission

levels without the presence of a 'hard lockdown' for extended periods of time, closely resembling the policy that most European counties implement regarding social distancing measures during the vaccination period.  $R_t$  is calculated as the largest eigenvalue of the next generation matrix, using an appropriate contact matrix. The contact matrices used for the calculations of the values of  $R_t$  were based on a social contacts survey assessing contacts in Greece; we have used the data collected in the second half of September 2020. This contact matrix informs the relative infectivity between age-groups but, importantly, the scale is set by the value of  $R_t$ .

We ran 1000 simulations for each scenario and computed the median as well as 90% equal-tailed uncertainty intervals. As precise data are not available for the precise course of infectivity and acquired immunity, three scenarios are considered.

*Worst Case Scenario*: It is assumed that, during the three months between the first and second dose (strategy II), the acquired immunity drops linearly to 34% (S1 Fig, Supporting information A). The effective infectious period of those vaccinated is reduced by 50% to 3 days.

*Baseline Scenario*: Here it is assumed that during the three months between the two doses (strategy II) the acquired immunity drops linearly to 50% and the infectious period of those vaccinated is set at 2 days (Fig 1).

*Optimistic Scenario*: In this case a constant immunity of 68% is assumed for the entire time between the first and second dose, and the infectious period lasts 2 days (S2 Fig, Supporting information A).

### Fraction of vaccines given to general population

Different percentages are considered for the proportion of the available vaccines distributed under strategy II. These are set to 0% (strategy I), 20%, 50% and 100% (strategy II); the resulting number of deaths and life years lost are computed in each of these cases. Moreover, in the model we assume that individuals due for the second dose have priority over those waiting to have their first dose, keeping the time interval between the two doses intact. The remaining doses available each day are given to unvaccinated individuals.

#### Vaccine availability

Two levels of vaccine availability are considered; a baseline level and a limited level with reduced number of vaccines, see S1 Table in Supporting information B.

#### Intention to get vaccinated

The populations' intention to get vaccinated is informed by a telephone survey contacted by [36]; see S1 Table in Supporting Information B. We assume that after the vaccination coverage of an age group reaches the percentage of people answering "*Probably/Definitely Yes*" to whether they intend to get vaccinated, the vaccination rollout continues to the next (younger) age group. The percentage of people answering "*Probably/Definitely No*" remains unvaccinated. The individuals answering "*Don't know/Don't answer*" are distributed among the two other groups according to their respected adjusted percentages.

## **Ethics Statement**

This is a simulation study so no human participants were involved. For this reason, review and approval of this study from an ethical committee were not necessary.

Since no human participants were recruited there are no available consent data or details.

Regarding the data survey based on the [36,37], since this survey was conducted by one of the authors on the current manuscript, we also provide an ethics statement for this. The protocol of the survey was approved by the Institutional Review Board of the Hellenic Scientific Committee for the Study of AIDS and STDs. Participants provided oral informed consent. The survey was conducted over the phone and participants were asked for their consent at the beginning.

# Results

Our main finding is that the optimal strategy in terms of the reduction in deaths and number of years lost, is the one that where all available vaccine doses are given under strategy II, using a time interval of three months between the two doses (Table 1).

Table 1. Comparison of strategy I (0% of population with 3 month interval) and strategy II (100% of population with 3 month interval)

Strategy II vs. strategy I	Total (%) reduction under strategy II during January-December 2021
Gain in number of deaths	579 (9.04%)
Gain in years of life	14802 (10.65%)

Comparison of strategy I and strategy II (at 100% doses given) for 2021 with  $R_t=1.2$ , under the baseline immunity scenario and standard vaccine availability. "Gain" refers to the number of *fewer* deaths and life years lost under strategy II (extended interval between doses).





Cumulative number of deaths over time when different percentages of doses are allocated under strategy II, with  $R_t=1.2$ , immunity drop between the two vaccine doses is at the baseline scenario, and with standard vaccine availability.

The results vary between different immunity waning scenarios and different values of  $R_t$ , but they are robust in that the optimal strategy is always found to be the one that allocates 100% of the available doses under strategy II. The intermediate allocations of 20% or 50% of the available doses for strategy II show similar mortality for the whole population with Strategy I. But because fewer younger people get infected and die, there is a reduction in total life years lost (S2-S4 Tables).

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Next, we examine the resulting figures for daily deaths, life years lost, and daily infections, under the baseline immunity waning scenario, with  $R_t$ =1.2, and with standard vaccine availability (Figs 3-5); detailed summaries of simulation results are presented in S2-S9 Tables given in Supporting information C; several additional results based on both the optimistic and worst-case scenarios are summarised in a web supplement at: <u>https://github.com/pbarmpounakis/Evaluating-the-effects-of-vaccine-rollout-policies-in-European-countries-A-simulation-study</u>



#### Fig 3. Number of new daily deaths.

Number of new daily deaths, when different percentages of doses are allocated under strategy II,  $R_t$ =1.2, immunity drop is at the baseline scenario, and with standard vaccine availability. [A zoomed-in version of this figure is available in the supplement, offering higher resolution locally.]



#### Fig 4. Total number of years of life lost

Total number of years of life lost when different percentages of doses are allocated under strategy II,  $R_t$ =1.2, immunity drop is at the baseline scenario, and with standard vaccine availability.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .



#### Fig 5. New daily infections

New daily infections when different percentages of doses are allocated under strategy II,  $R_t=1.2$ , immunity drop is at the baseline scenario, and with standard vaccine availability.

# Discussion

After the vaccination of medical personnel, high-risk individuals, and people aged over 75 years old with a time interval of 3-4 weeks between doses, the strategy of vaccinating the rest of the population with an interval of three months between the two doses (strategy II) can result in a significantly reduced number of deaths and years of life lost. When only 20% or 50% of the available vaccines are distributed using strategy II, the results are not significantly different to strategy I in terms of deaths, although they do provide an improvement in the number of life years saved. In conclusion, rolling out 100% of the available vaccines using the delayed second dose strategy appears to be the most effective option.

In the absence of detailed social contact data between different groups, we accounted for age groups as a surrogate for population composition, and we used the contact rate data between different age-groups from the recent survey [37]. Therefore, the results reported here offer a conservative assessment since no attempt is made to prioritize individuals with many contacts such as mass transit employees, those working in the hospitality industry, super-markets and so on. Consequently, in practice, the benefits are expected to be even greater if a more targeted approach is adopted.

We used a multitype, age-structured, stochastic epidemic model with constant transmission rate and constant exposed and infectious periods. Although this approach of course has some limitations, they are not expected to materially affect the results. First, in our model, we assumed that vaccine efficacy was mediated by a reduction in infections and not just in clinical disease. Recent modelling studies suggest that, if vaccines reduce symptomatic infection only, then the optimal protection for minimising deaths is obtained by prioritising older individuals [15]. This assumption is realistic especially in view of recent data suggesting that COVID-19 vaccines are indeed effective in the prevention of infection at least before the occurrence of the Delta strain [38,39]. Second, we assessed two scenarios for viral transmission rates ( $R_t$ =1.2 and  $R_t$ =1.4). For higher transmission levels, a recent study similarly found that vaccinating high-risk groups first constituted the optimal use of available vaccines [15]. On the other hand, moderate transmission levels are a more realistic scenario as most counties continue to implement moderate

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

social distancing measures during vaccination. Alternative scenarios may be considered for the transmission rate, but the overall outcomes are not expected to be substantially influenced as the current assumptions regarding  $R_t$  may be thought of as an "average" version of a time-varying rate. In addition, it is known [1] that the final size of a stochastic epidemic is invariant to the presence of an exposed period and to different distributional assumptions on the infectious period duration. Hence, these assumptions will not alter the conclusions of this work. Other recent relevant results supporting our assumptions include [40,41].

The main conclusions of the present study and all relevant assumptions made about vaccine efficacy are in broad agreement with the results obtained using optimization techniques for a model calibrated using data from Italy [18], despite the fact that the authors only allowed for the vaccine to protect against transmission and not disease. Recent results from Israel suggest that there is also protection against hospitalization and death [35] and therefore these results may be conservative. Similar conclusions are reported when varying vaccine availability and using alternative efficacy assumptions [19]. Assuming that efficacy remains constant after the first dose, [42] used simulation and showed that the effectiveness of vaccination programmes in reducing infections, hospitalizations and deaths is maximized with a delay of 12 to 15 weeks for both the Pfizer and Moderna vaccines. Similar recommendations on delaying the second dose for individuals below the age of 65 are made in [43].

Although we have chosen to primarily emphasize the results of the proposed approach in terms of quantities of interest in public health, additional gains are to be expected in terms of social and economic aspects of public life by offering faster vaccine coverage to the economically active population. An empirical application of the proposed approach is effectively followed in the United Kingdom and Canada, and the outcome seems to be a significantly faster reduction in SARS-CoV-2 circulation.

Overall, our results clearly indicate that, in the presence of a limited vaccine supply, distributing all available doses with a 3-month intermediate time interval could offer important advantages in terms of public health as well as to the wider society and the economy.

# References

- 1. Andersson, H., & Britton, T. (2000). Stochastic Epidemic Models and Their Statistical Analysis. Lecture Notes in Statistics, vol 151, Springer, New York, NY.
- 2. Wang, W., et al. (2020). Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study. BMJ 2020;371:m4704.
- 3. FDA (2020). FDA Briefing Document, Moderna COVID-19 Vaccine, https://www.fda.gov/media/144434/download. Last accessed December 27, 2020.
- Polack, F.P., et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383(27), 2603-2615.
- 5. Voysey, M. et al. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, The Lancet. 397:10269, 99-111.
- 6. Bollyky, T.J. (2021). U.S. COVID-19 Vaccination Challenges Go Beyond Supply. Annals of Internal Medicine. 174:558–559.
- Lewnard, J.A. et al., (2020). Scientific and ethical basis for social-distancing interventions against COVID-19. The Lancet Infectious Diseases, volume 20, issue 6, 631-633.
- 8. Taipale, J., Kontoyiannis, I., Linnarsson, S. (2021). Population-scale testing can suppress the spread of infectious disease. arXiv:2104.06857 [q-bio.PE].
- Emanuel, E.J., Persad, G., Upshur, R., Thome, B., Parker, M., Glickman, A., et al., (2020). Fair Allocation of Scarce Medical Resources in the Time of Covid-19. New England Journal of Medicine 382(21), 2049-2055.
- 10. Persad, G., Wertheimer, A., Emanuel, E.J., (2009). Principles for allocation of scarce medical interventions. The Lancet, 373(9661), 423-431.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- Bubar KM, Reinholt K, Kissler SM, Lipsitch M, Cobey S, Grad YH, Larremore DB. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021 Feb 26;371(6532):916-921. doi: 10.1126/science.abe6959. Epub 2021 Jan 21. PMID: 33479118; PMCID: PMC7963218.
- 12. Matrajt, L., Eaton, J., Leung, T., Brown, E.R. (2020). Vaccine optimization for COVID-19: Who to vaccinate first? Science Advances, 7(6).
- 13. Official statement for the delay of 2<sup>nd</sup> dose vaccines United Kingdom: https://www.gov.uk/government/news/statement-from-the-uk-chief-medicalofficers-on-the-prioritisation-of-first-doses-of-covid-19-vaccines
- 14. Official statement for the delay of 2<sup>nd</sup> dose vaccines Canada: <u>https://www.canada.ca/en/public-health/services/immunization/national-advisory-</u> <u>committee-on-immunization-naci/recommendations-use-covid-19-vaccines.html</u>
- Matrajt, L., Eaton, J., Leung, T., Dimitrov, D., Schiffer, J.T., Swan, D.A., et al. (2021). Optimizing vaccine allocation for COVID-19 vaccines: potential role of single-dose vaccination. medRxiv, 2020.2012.2031. 20249099.
- 16. Paltiel, A. D., Schwartz, J. L., Zheng, A., Walensky, R. P. (2021a). Clinical Outcomes of a COVID-19 Vaccine: Implementation Over Efficacy. Health Affairs, 10-1377.
- Paltiel, A.D., Zheng, A., Schwartz, J.L. (2021b). Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. Annals of Internal Medicine, Volume 174, Issue 4, pp. 568-570.
- Silva, P. J. S., Sagastizábal, C, Nonato, L. G., Struchiner, C. J., Pereira, T., (2021) Optimized delay of the second COVID-19 vaccine dose reduces ICU admissions. Proceedings of the National Academy of Sciences.
- 19. Ferreira et al. (2021). Assessing optimal time between doses in two-dose vaccination regimen in an ongoing epidemic of SARS-CoV-2. medRxiv 2021.07.28.21261200.
- Moore, S. & Hill, E., Tildesley, M., Dyson, L., Keeling, M., (2021). Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study. The Lancet Infectious Diseases. 21. 10.1016/S1473-3099(21)00143-2.
- Diekmann, O., Heesterbeek, H., Britton, T., Mathematical Tools for Understanding Infectious Disease Dynamics. Princeton University Press, pp. 516, ISBN 978-0-691-15539-5.
- Parino, F, Zino, L, Calafiore, GC, Rizzo, A. A model predictive control approach to optimally devise a two-dose vaccination rollout: A case study on COVID-19 in Italy. Int J Robust Nonlinear Control. 2021; 1– 16. <u>https://doi.org/10.1002/rnc.5728</u>.
- 23. Li, R., et al. (2020). Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science, Vol. 368, Issue 6490, pp. 489-493.
- 24. Lauer, S.A., Grantz, K.H., Bi, Q. et al. (2020). The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of Internal Medicine, 172(9): 577-582.
- 25. Liu, T., et al. (2020) Transmission Dynamics of 2019 Novel Coronavirus (2019-nCoV) (1/25/2020). Available at SSRN: https://ssrn.com/abstract=3526307 or http://dx.doi.org/10.2139/ssrn.3526307 .
- He, X., Lau, E.H.Y., Wu, P. et al. (2020). Temporal dynamics in viral shedding and transmissibility of COVID-19. Nature Medicine 26(5):672–675.
- Ganyani, T., Kremer, C., Chen, D., et al. (2020). Estimating the generation interval for coronavirus disease (COVID-19) based on symptom onset data. Eurosurveillance, 25(17):2000257.
- 28. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y., et al. (2020). Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. New England Journal of Medicine, 382(13):1199–207.
- 29. Cereda, D. et al. (2020). The early phase of the COVID-19 outbreak in Lombardy, Italy. arXiv e-prints; arXiv:2003.09320.
- 30. Bi, Q. et al. (2020). Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. The Lancet Infectious Diseases, 20(8): 911-919.
- Lavvezzo, E., Franchin, E., Ciavarella, C., Cuomo-Dannenburg, G., Barzon, L., Del Vecchio, C., et al. (2020). Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature. 584, 425-429.
- 32. de Gier, B., et al. (2021). Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), August-September 2021, the Netherlands, medRxiv: 10.1101/2021.10.14.21264959.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

- 33. Singanayagam, A., et al. (2021). Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study, The Lancet Infectious Diseases, Elsevier: 1473-3099, https://doi.org/10.1016/S1473-3099(21)00648-4.
- 34. CDC (2021). Covid-19 Pandemic and Planning Scenarios, US Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/hcp/planningscenarios.html, March 19, 2021 update.
- 35. Haas, J.E., Angulo, F.J., McLaughlin, J.M. et al. (2021). Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance. The Lancet, 397(10287): 1819-1829.
- 36. Sypsa, V., Roussos, S., Engeli, V., Paraskevis, D., Tsiodras, S., Hatzakis, A. (2021) Trends in COVID-19 vaccination intent, determinants and reasons for vaccine hesitancy: results from repeated cross-sectional surveys in the adult general population of Greece during November 2020-June 2021, medRxiv 2021.06.23.21259376.
- 37. Sypsa, V., et al. (2021). Effects of Social Distancing Measures during the First Epidemic Wave of Severe Acute Respiratory Syndrome Infection, Greece. Emerging Infectious Diseases. 27(2): 452-462.
- Amit, S., Regev-Yochay, G., Afek, A., Kreiss, Y., Leshem, E. (2021). Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet, 397 (10277), 875-877.
- Thompson, M.G. et al. (2021). Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR. Morbidity and Mortality Weekly Report 70(13), 495-500.
- 40. Tuite, A.R, Zhu, L., Fisman, D.N., Salomon, J.A. (2021). Alternative dose allocation strategies to increase benefits from constrained COVID-19 vaccine supply. Annals of internal medicine, 174(4), 570-572.
- 41. Vasileiou, E., et al. (2021). Effectiveness of first dose of COVID-19 vaccines against hospital admissions in Scotland: national prospective cohort study of 5.4 million people. The Lancet preprints, February 2021, available at SSRN: <a href="https://srn.com/abstract=3789264">https://srn.com/abstract=3789264</a>.
- 42. Moghadas SM, Vilches TN, Zhang K, Nourbakhsh S, Sah P, et al. (2021) Evaluation of COVID-19 vaccination strategies with a delayed second dose. PLOS Biology 19(4): e3001211.
- 43. Romero-Brufau, S., (2021) Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.
- 44. Koh, W.C. et al. (2020). What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors. PLoS ONE 15(10): e0240205.
- 45. ELSTAT (2021), Greek Statistics Authority, <u>https://www.statistics.gr/</u>.
- 46. Skowronski D.M., De Serres G. (2020). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine*, 2021.
- 47. Baden, L. R. et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England. Journal of Medicine, 384:403-416.

# Supporting information

# **Supporting information A**

Graphical presentation of different scenarios



S1 Fig. Schematic representation of the S(V)EIR epidemic model for the worst-case scenario regarding immunity waning.



S2 Fig. Schematic representation of the S(V)EIR epidemic model for the optimistic scenario regarding immunity waning.

# Supporting information B

## S1 Table. Model Assumptions

R:   1.2     1.4   Set to assess different levels of transmission. R; is calculated as the largest eigenvalue of the next generation matrix, using an appropriate contact matrix (see below).     Total population   10816287     Population by age goup   0-17: 1908003 (17.6%) 18-39: 3200713 (29.5%) 40-64: 3539972 (32.7%) 65+: 2167599 (20%)   Data from the Greek Statistics Authority [45]. Data from [45].     Medical personnel population   Around 250000   Rough estimated number of infected individuals, with the estimated number of infected individuals, with the estimated number of infected individuals ~ 700000.     Medical personnel population   Around 250000   Rough estimate form data from [45].     Duration of infectous period for non- vaccinated people   6 days   Ser [N-estimated number of infectous period for non- vaccinated people     Duration of infectous period for non- vaccinated people   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Serial interval of approximately 6 days. [29-31].     Age specific infection fatality ratios (IFR)   0-17: 0.00003 40-53: 0.00020 40-64: 2.5e-04 40-64: 2.5e-04   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 18-39   40-64   65+ 40-64: 2.5e-04     Matrix of contacts   0-17: 18-39   40-64   65+ 40-64: 2.5e-04   5+ brobable of dying [35].	Parameters	Value					<b>Comments-References</b>
1.4   Image: I	R <sub>t</sub>	1.2					Set to assess different
Area   R, is calculated as the largest eigenvalue of the next generation matrix, using an appropriate contact matrix (see below).     We consider reduced infection probability for children by a8% [44].   We consider reduced infection probability for children by 48% [44].     Population by age goup   0-17: 1908003 (17.6%)   Data from the Greek Statistics Authority [45].     Population by age goup   0-17: 1908003 (29.5%)   Data from the Greek Statistics Authority [45].     We assume that   S = [N-estimated number of infected individuals, with the estimated number of infected individuals, with the estimated number of infected individuals with the estimated number of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].     Duration of infected for non-vaccinated and vaccinated people   6 days   Serial interval of approximately 2 days prior to the occurrence of symptoms[26-28].     Duration of infected infection specific for vaccinated persons   3 days (worst case scenario)   Serial interval of approximately 6 days. [29-31].     Age specific infection fatality 18-39: 0.00002   0-17: 0.15e-06   We consider vaccinated people area     people   0-17: 0.15e-06   We consider vaccinated people area   Data from [34].     Age specific infection fatality 18-39: 0.00020   0-17: 18-39		1.4					levels of transmission.
Iargest eigenvalue of the next generation matrix, using an appropriate contact matrix (see below). We consider reduced infection probability for children by 48% [44].     Total population population generation matrix, using an appropriate contact matrix (see below). We consider reduced infection probability for children by 48% [44].     Population by age goup age goup age goup for the statistics Authority [45].     Medical personnel population 2   0-17: 1908003 (17.6%) (32.7%) (40-64: 3539972 (32.7%) (5+: 2167599 (20%))   Data from [45].     Medical personnel population 2   Around 250000   Rough estimate form data from [45]     Exposed period 2   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectious starts approximately 2 days period for non-vaccinate and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated people     Duration of infectious period for non-vaccinated people   3 days (worst case scenario) and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated period for ono-vaccine efficiency)     Age specific infection fatality 18-39: 0.00020 ratios (IFR) do -17: 0.5000   Data from [34].   Data from [34].     Age specific ratios (IFR) for vaccinated people   0-17: 0.5000   We consider vaccinated people resors     Matrix of contacts   0-17: 18-39   40-64   65+     Matrix of contacts   0-17: 18-39   40-64							$R_t$ is calculated as the
next generation matrix, using an appropriate contact matrix (see below).   using an appropriate contact matrix (see below).     Total population   10816287   Data from the Greek Statistics Authority [45].     Population by age goup   0-17: 1908003 (17.6%)   Data from [45].     We assume that   S = [A-estimated number of infected individuals ~ 700000.     Medical period   Around 250000   Rough estimate form [45].     Population f   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days.     people   6 days   Serial interval of approximately 6 days.     Duration of infectious people   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated people approximately 6 days.     Duration of infectious period for non-vaccinated persons   3 days (worst case scenario) and optimistic scenario and opt							largest eigenvalue of the
Image: specific period for non-vaccinated people 2 days for non-vaccinated and vaccinated people Based on an average incubation time of approximately 5 days. [29-31].   Duration of infectious period for non-vaccinated people 2 days for non-vaccinated and vaccinated people Serial interval of approximately 6 days. [29-31].   Duration of infectious period for non-vaccinated people 3 days (worst case scenario) 2 days (most case scenario) and optimistic scenario regarding vaccine efficiency) Serial interval of approximately 6 days. [29-31].   Age specific infection fatality ratios (IFR) for vaccinated people 0-17: 0.00003 Assuming that infectious period to one half (worst case scenario) at 59: 1.02-05   Age specific infection fatality ratios (IFR) for vaccinated people 0-17: 0.12: 0							next generation matrix,
Contact matrix (see below).   Contact matrix (see below).     Total population   10816287     Population by age goup   0-17: 1908003 (17.6%) 18-39: 3200713 (29.5%) 40-64: 3539972 (32.7%) 65+: 2167599 (20%)   Data from [45].     Medical personnel population   Around 250000   Rough estimated number of infected individuals ~ 700000.     Medical personnel population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 2 days [23-25] and assuming that infectiousness starts approximately 2 days [23-25] and assuming that infectiousness starts approximately 5 days. [24-25] and assuming that infectiousness starts approximately 5 days. [29-31].     Duration of infectious period for vaccinated people   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinations decrease the infectious speid to one third (baseline scenario and optimistic scenario and							using an appropriate
Duration of infectious period for non-vaccinated and vaccinated people 0 -17: 1000003 (17: 0.0000) 0 -17: 0.00003 (17: 0.0000) 0 -17: 0.00003 (17							contact matrix (see
Medical population of infection graduality for children by 48% [44].   Data from the Greek Statistics Authority [45].     Population by age goup   0-17: 1908003 (17.6%)   Data from the Greek Statistics Authority [45].     Bage goup   0-17: 1908003 (17.6%)   Data from the Greek Statistics Authority [45].     Population by age goup   0-17: 1908003 (17.6%)   We assume that S = [N-estimated number of infected individuals ~ 700000.     Rough estimate form data from [45].   Statistics Authority [45].   Data from [45].     personnel population   2 days for non-vaccinated and vaccinated people   Based on an average incubation inme of approximately 5 days [23-25] and assuming that infectionses statas approximately 2 days prior to the occurrence of symptoms[26-28].     Duration of infectious people   6 days   Serial interval of approximately 6 days. [29-31].     Duration of infectious people   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated people     Duration of infection fatality ratios (IFR) of 4.39: 0.00020   Gold approximately 6 days. [29-31].   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 0.00003   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 18-39 40-64   65+     Matrix of contax   0-17							below).
Total population   10816287   Data from the Greek Statistics Authority [45].     Population by age goup   0-17: 1908003 (17.6%) 18-39: 3200713 (29.5%) 40-64: 3539972 (32.7%) 65+: 2167599 (20%)   Data from [45]. We assume that 65+: 2167599 (20%)   We assume that setimated number of infected individuals, with the estimated number of infected individuals ~ 700000.     Medical personnel population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average infectious period for non-vaccinated and vaccinated people     Duration of infectious period for non-vaccinated people   6 days   Serial interval of approximately 2 days. [29-31].     Duration of infectious period for vaccinated persons   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated to one third (baseline scenario and optimistic scenario, regarding vaccine efficiency)     Age specific infection fatality ratios (IFR) affection fatality ratios (IFR) for vaccinated people   0-17: 0.00003 18-39: 1.0-05 40-64: 2.7e-03   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 18-39   40-64   65+ 5     Matrix of contaxts   0-17   18-39   40-64   65+ 5   based on social contacts							We consider reduced
Total population     10816287     Data from the Greek Statistics Authority [45].       Population by age goup     0-17: 1908003 (17.6%) 18-39: 3200713 (29.5%) 40-64: 3539972 (32.7%)     Data from [45].       Medical personnel population     Around 250000     Rough estimate number of infected individuals ~ 700000.       Medical personnel population     Around 250000     Rough estimate form data from [45]       Duration of infectious period for non- vaccinated people     2 days for non-vaccinated and vaccinated people     Based on an average incubation time of approximately 5 days [23-25] and assuming that infectious period for non- vaccinated people     Based on an average incubation time of approximately 6 days. [29-31].       Duration of infectious period for non- vaccinated people     6 days     Serial interval of approximately 6 days. [29-31].       Duration of infectious period for vaccinated persons     3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)     Assuming, that vaccinated persons       Age specific infection fatality ratios (IFR) for vaccinated people     0-17: 0.00003 18-39: 1.0e-05 40-64: 2.7e-03     Data from [34].       Age specific infection fatality ratios (IFR) for vaccinated people     0-17: 18-39 40-64 65+ 0-17     Based on social contacts surveys assessing							infection probability for
Total population   Total 250*   Statistics Authority [45].     Population by age goup   0-17: 1908003 (17.6%) 40-64: 3539972 (32.7%)   Data from [45].     Medical personnel population   Around 250000   Rough estimate form data from [45]     Medical personnel population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectiouss period for non- vaccinated people     Duration of infectious persons   6 days   Serial interval of approximately 6 days. [29-31].     Age specific infection fatality ratios (IFR) for vaccinated people   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated people     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 0.00003 18-39: 1.0e-05 vaccinated people   Data from [31].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 18-39 40-64 65+: 2.7e-03   Medical 65+: 0-17	Tatal nanulation	10016207	,				Children by 48% [44].
Population by age goup   0-17: 1908003 (17.6%) 18-39: 3200713 (29.5%) 40-64: 3539972 (32.7%) 65+: 2167599 (20%)   Data from [45]. We assume that number of infected individuals], with the estimated number of infected individuals ~ 700000.     Medical personnel population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectious period for non- vaccinated people     Duration of infectious period for vaccinated persons   6 days   Serial interval of approximately 6 days. [29-31].     Duration of infectious period for vaccinated persons   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario. 132,33]     Age specific infection fatality ratios (IFR) do-64: 0.00500 65+: 2.7e-03   0-17: 18-39   40-64   65+: 0-17   We consider vaccinated people     Matrix of contaxts   0-177   18-39   40-64   65+: 0-47   Based on social contacts surveys assessing	Total population	10816287					Statistics Authority [45].
age goup18-39: 3200713 (29.5%) $40-64: 3539972 (32.7%)$ $65+: 2167599 (20%)$ We assume that $S = [N-estimatednumber of infectedindividuals], with theestimated number ofinfected individuals], with theestimated number ofapproximately 2 days[23-25] and assumingthat infectiousness startsapproximately 2 daysprior to the occurrenceof symptoms[26-28].Duration ofinfectiousperoid for non-vaccinatedpersons6 daysSerial interval ofapproximately 6 days.[29-31].Duration ofinfectiouspersons3 days (worst case scenario)2 days (baseline scenario and optimisticscenario and optimisticscenario and optimisticscenario and optimisticscenario and optimisticscenario and optimisticscenario in approximately 2 days(23-33]Age specificinfection fatalityratios (IFR)0-17: 0.0000318-39: 1.0e-0540-64: 2.5e-0465+: 2.7e-03Data from [34].Age specificinfection fatalityratios (IFR) forvaccinatedpeople0-17: 18-3940-6465+: 2.7e-03We consider vaccinatedpeople40-64: 2.5e-0465+: 2.7e-03Matrix ofcontaxts0-17: 18-3940-6465+: 2.7e-03Based on social contaxts$	Population by	0-17: 19	08003 (	(17.6%)			Data from [45].
$ \begin{array}{ c c c c c } \hline & 40-64: 3539972 (32.7\%) & S = [N-estimated number of infected individuals], with the estimated number of infected individuals ~ 700000. \\ \hline & Around 250000 & Rough estimate form data from [45] \\ \hline & population & 2 days for non-vaccinated and vaccinated people & 2 days for non-vaccinated people & 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency) & Assuming, that vaccinated persons & 3 days (worst case scenario) & 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency) & Assuming, that vaccinated people & 2 days (baseline scenario and optimistic scenario) and potimistic scenario and optimistic scenario and optimistic scenario) [32,33] & Age specific infection fatality ratios (IFR) & 0-17: 01.5e-06 & 18-39: 0.00020 & 40-64: 0.00500 & 65+: 0.05400 & 65+: 0.0$	age goup	18-39: 3	200713	໌ (29.5%໌	)		We assume that
65+: 2167599 (20%)   number of infected individuals, with the estimated number of infected individuals, with the estimated number of infected individuals, ~700000.     Medical personnel population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].     Duration of infectious period for non-vaccinated people   6 days   Serial interval of approximately 6 days. [29-31].     Duration of infectious period for non-vaccinated people   3 days (worst case scenario) and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated period to one half (worst case scenario). [29-31].     Age specific infectious farality ratios (IFR)   0-17: 0.00003   Data from [34].     Age specific infection fatality ratios (IFR) for do: 4.25e-04   Data from [34].     Matrix of constanted people   Data from [35].   Probable of dying [35].     Matrix of constarted people   0-17   16.76   4.34   3.59   0.46   Based on social contacts surveys assessing		40-64: 35	39972	(32.7%)			S = [N-estimated]
Medical personnel population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].     Duration of infectious period for non- vaccinated people   6 days   Serial interval of approximately 6 days. [29-31].     Duration of infectious period for vaccinated persons   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccination sdecrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]     Age specific infection fatality ratios (IFR) of S+: 0.05400   0-17: 0.5e-06 (0-17: 0.5e-04 (0-44: 2.5e-04   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   16.76   4.34   3.59   0.46		65+: 216	7599 (2	20%)			number of infected
Medical personnel population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].     Duration of infectious period for non- vaccinated people   6 days   Serial interval of approximately 6 days. [29-31].     Duration of infectious period for non- vaccinated people   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinations decrease the infectious period to one thinf (worst case scenario). [32,33]     Age specific infection fatality ratios (IFR)   0-17: 0.00003 (18-39: 1.0e-05 40-64: 0.0500 65+: 2.7e-03   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17. 18-39   40-64   65+ survey assessing							individuals], with the
Medical personnel populationAround 250000Rough estimate form data from [45]Exposed period2 days for non-vaccinated and vaccinated peopleBased on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].Duration of infectious people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious period for non- vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinated personsAge specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Metocal 40-64: 2.5e-04 40-64: 2.5e-04We consider vaccinated people are 95% less probable of dying [35].Age specific infection fatality ratios (IFR) for vaccinated people0-1718-3940-6465+ 65+:Matrix of contacts0-1718-3940-6465+ 65+:Based on social contacts surveys assessing							estimated number of
Medical personnel populationAround 250000Rough estimate form data from [45]Exposed period2 days for non-vaccinated and vaccinated peopleBased on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].Duration of infectious people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious people3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinated personsAge specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.75400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 18-39 40-64: 0.434We consider vaccinated peopleAge specific infection fatality ratios (IFR) for vaccinated people0-17: 18-76 40-64: 0.434Matrix of 65+: 2.7e-03We consider vaccinated people							infected individuals ~
Predictal population   Around 250000   Rough estimate form data from [45]     Exposed period   2 days for non-vaccinated and vaccinated people   Based on an average incubation time of approximately 5 days [23-25] and assuming that infectiousses starts approximately 2 days prior to the occurrence of symptoms[26-28].     Duration of infectious people   6 days   Serial interval of approximately 6 days. [29-31].     Duration of infectious people   3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)   Assuming, that vaccinated persons     Age specific infection fatality ratios (IFR)   0-17: 0.00003 (5+: 0.05400   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 0.5e-06 (5+: 2.7e-03   We consider vaccinated people     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 18-39   40-64   65+: probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+: probable of dying [35].	Madical	Around 20	-0000				700000.
period for period for nor-vaccinated people2 days for non-vaccinated and vaccinated peopleBased on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].Duration of infectious period for non- vaccinated people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinated period for 0 approximately 6 days. [29-31].Age specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Assuming, that vaccinated 40-64: 0.00500 65+: 2.7e-03Data from [34].Age specific infection fatality vaccinated people0-17: 18-39 10-6740-64 10-64Me consider vaccinated peopleAge specific infection fatality vaccinated people0-17: 18-39 10-6740-64 10-6465+ 10-64Matrix of contacts0-17 16.7618-39 10-640.46465+ 10-46Matrix of contacts0-17 16.7618-39 10-640.46Based on social contacts	neuicai	Around 2:	50000				data from [45]
Duration2 days for non-vaccinated and vaccinated peopleBased on an average incubation time of approximately 5 days [23-25] and assuming that infectiousness starts approximately 2 days prior to the occurrence of symptoms[26-28].Duration of infectious period for non- vaccinated people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious period for vaccinated people3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinated peopleAge specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Assuming, that vaccinated peopleAge specific infection fatality ratios (IFR) for vaccinated people0-17: 0.15e-06 40-64: 2.5e-04 65+: 2.7e-03We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-17< 18-39 16.7640-64 4.3465+ 3.59Based on social contacts surveys assessing	population						
Duration of infectious people6 daysSerial interval of approximately 2 days prior to the occurrence of symptoms[26-28].Duration of infectious people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious people3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinated personsAge specific infection (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Assuming, that vaccinated peopleAssuming, that vaccinated peopleAge specific infection fatality ratios (IFR)0-17: 0.5e-06 18-39: 1.0e-05 65+: 2.7e-03We consider vaccinated peopleAge specific infection fatality ratios (IFR) for vaccinated people0-17: 18-39 40-64 65+: 2.7e-03We consider vaccinated peopleMatrix of contacts0-17: 18-39 0.40-64 0.464.34 3.59Based on social contacts surveys assessing	Exposed period	2 days for	non-va	accinated	l and vacci	nated	Based on an average
Duration of infectious period for non- vaccinated period for non- vaccinated period for infectious speriod for infectious period for infectious period for infectious period for infectious period for infectious period for infectious period for vaccinated period for vaccinated fifection fatality fifection fatality for vaccinated people0-1718-3940-6465+ 65+ 65+Based on social contacts surveys assessingAge specific infection fatality ratios (IFR) for vaccinated people0-1718-3940-6465+ 65+Based on social contacts		neonle				nateu	incubation time of
Duration of infectious period for non- vaccinated people6 daysSerial interval of approximately 2 days prior to the occurrence of symptoms[26-28].Duration of infectious people3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Serial interval of approximately 6 days. [29-31].Duration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinated personsAge specific infection fatality ratios (IFR)0-17: 0.00003 18-39: 0.00020 40-64: 0.05500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 18-39 40-64 65+: 2.7e-03We consider vaccinated peopleMatrix of contacts0-17 16.7618-39 4.340.46Based on social contacts surveys assessing		people					approximately 5 days
Duration of infectious period for non- vaccinated people6 daysSerial interval of approximately 2 days prior to the occurrence of symptoms[26-28].Duration of infectious people3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinated personsDuration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]Age specific infection fatality ratios (IFR)0-17: 0.00003 18-39: 1.0e-05 40-64: 2.5e-04 40-64: 2.5e-04 40-64: 2.5e-04We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1718-3940-6465+ 65+							[23-25] and assuming
Age specific infection fatality ratios (IFR)0-17: 0.00003 1-15:e-06 0-17: 01.5e-06 0-17: 01.5e-06Assuming, that vaccinated peopleAssuming, that vaccinated peopleDuration of infectious people3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario and optimistic succinated peopleMatrix of contacts0-1718-3940-6465+ 45+Based on social contacts							that infectiousness starts
Duration of infectious period for non- vaccinated people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious people3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario. regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario. regarding vaccine efficiency)Age specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Data from [34].Age specific 							approximately 2 days
Duration of infectious period for non- vaccinated people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario regarding vaccine efficiency)Age specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 18-39 40-64: 2.5e-04 65+: 2.7e-03We consider vaccinated peopleMatrix of contacts0-1718-39 40-6440-64 65+Matrix of contacts0-1718-39 40-6440-64 65+Matrix of contacts0-1718-39 40-6440-64 65+Matrix of contacts0-1718-39 40-6440-64 65+							prior to the occurrence
Duration of infectious people6 daysSerial interval of approximately 6 days. [29-31].Duration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency)Age specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.05400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 01.5e-06 40-64: 2.5e-04 40-64: 2.5e-04We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-17< 18-39 0-1740-64 18-3965+ 18-39Matrix of contacts0-1718-39 0-4640-64 65+ 65+							of symptoms[26-28].
infectious period for non- vaccinated peopleapproximately 6 days. [29-31].Duration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]Age specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 18-39 40-64: 2.5e-04 40-64: 2.5e-04We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-39 40-64 4.344.59 3.59Based on social contacts surveys assessing	Duration of	6 days					Serial interval of
period for non- vaccinated people[29-31].Duration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario and optimistic scenario, regarding vaccine efficiency)Age specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1718-3940-6465+ 65+O-1716.764.343.590.46surveys assessing	infectious						approximately 6 days.
vaccinated people3 days (worst case scenario)Assuming, that vaccinations decrease the infectious period for scenario, regarding vaccine efficiency)vaccinated personsScenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]Age specific infection fatality ratios (IFR)0-17: 0.00003 18-39: 0.00020 40-64: 0.00500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 18-39 65+: 2.7e-03We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-39 16.7640-64 4.3465+ 3.590.460-1718-39 40-6465+ 65+Based on social contacts surveys assessing	period for non-						[29-31].
peopleAssuming, thatDuration of infectious period for vaccinated persons3 days (worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency)Age specific infection fatality ratios (IFR)0-17: 0.00003 18-39: 0.00020 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR) for vaccinated people0-17: 0.5e-06 40-64: 2.5e-04 65+: 2.7e-03We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-17< 18-39 0.4640-64 55+Based on social contacts surveys assessing	vaccinated						
Duration of infectious period for vaccinated persons3 days (Worst case scenario) 2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Assuming, that vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]Age specific infection fatality ratios (IFR)0-17: 0.00003 40-64: 0.00500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR)0-17: 01.5e-06 40-64: 2.5e-04 65+: 2.7e-03We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-3940-6465+ 65+:Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1718-3940-6465+ 65+	people	2 1					
Infrectious period for vaccinated persons2 days (baseline scenario and optimistic scenario, regarding vaccine efficiency)Vaccinations decrease the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]Age specific infection fatality ratios (IFR)0-17: 0.00003 18-39: 0.00020 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR)0-17: 0.05400 40-64: 2.5e-04 40-64: 2.5e-04We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1718-3940-6465+ 65+	Duration of	3 days (w	orst cas	se scena	rio)	:	Assuming, that
period for vaccinated personsscenario, regarding vaccine enciency)the infectious period to one third (baseline scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]Age specific infection fatality ratios (IFR)0-17: 0.00003 18-39: 0.00020 40-64: 0.00500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR)0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1716.764.343.590.46	Infectious	2 days (b	aseline	scenario	and optim	ISTIC	vaccinations decrease
Vaccinated personsOne third (baseline scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]Age specific infection fatality ratios (IFR)0-17: 0.00003 18-39: 0.00020 40-64: 0.00500 65+: 0.05400Data from [34].Age specific infection fatality ratios (IFR)0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03We consider vaccinated people are 95% less probable of dying [35].Matrix of contacts0-1718-3940-6465+ 65+Matrix of contacts0-1716.764.343.590.46	period for	scenario,	regarui	ng vacci	ie enicienc	.y)	the infectious period to
persons   scenario and optimistic scenario regarding vaccine efficiency) and to one half (worst case scenario). [32,33]     Age specific infection fatality ratios (IFR)   0-17: 0.00003 40-64: 0.00500 65+: 0.05400   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+ 65+   Based on social contacts surveys assessing	vaccinated						one uniru (Dasenne
Age specific infection fatality ratios (IFR)   0-17: 0.00003 18-39: 0.00020 40-64: 0.00500 65+: 0.05400   Data from [34].     Age specific infection fatality ratios (IFR)   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+     Based on social contacts surveys assessing	persons						scenario regarding
Age specific infection fatality ratios (IFR)   0-17: 0.00003 18-39: 0.00020 40-64: 0.00500 65+: 0.05400   Data from [34].     Age specific infection fatality ratios (IFR)   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+     Based on social contacts surveys assessing   0-17   18-39   0.46							vaccine efficiency) and
Age specific infection fatality ratios (IFR)   0-17: 0.00003 18-39: 0.00020 40-64: 0.00500 65+: 0.05400   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+ 40-64   Based on social contacts surveys assessing							to one half (worst case
Age specific infection fatality ratios (IFR)   0-17: 0.00003 18-39: 0.00020 40-64: 0.00500 65+: 0.05400   Data from [34].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+     Based on social contacts surveys assessing							scenario), [32,33]
infection fatality ratios (IFR)   18-39: 0.00020 40-64: 0.00500 65+: 0.05400   We consider vaccinated people are 95% less probable of dying [35].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+ 65+	Age specific	0-17: 0.0	0003				Data from [34].
ratios (IFR)   40-64: 0.00500 65+: 0.05400   We consider vaccinated people are 95% less probable of dying [35].     Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+     Based on social contacts surveys assessing	infection fatality	18-39: 0	.00020				
65+: 0.05400   Age specific   0-17: 01.5e-06   We consider vaccinated people are 95% less probable of dying [35].     ratios (IFR) for vaccinated   40-64: 2.5e-04   probable of dying [35].     vaccinated   65+: 2.7e-03   People     Matrix of contacts   0-17   18-39   40-64   65+     Description   0-17   18-39   40-64   65+   Based on social contacts	ratios (IFR)	40-64:0.	00500				
Age specific infection fatality ratios (IFR) for vaccinated people   0-17: 01.5e-06 18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   We consider vaccinated people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+     Based on social contacts surveys assessing		65+: 0.05	5400				
infection fatality ratios (IFR) for vaccinated people   18-39: 1.0e-05 40-64: 2.5e-04 65+: 2.7e-03   people are 95% less probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+     Based on social contacts surveys assessing	Age specific	0-17:01.	5e-06				We consider vaccinated
ratios (IFR) for vaccinated people   40-64: 2.5e-04   probable of dying [35].     Matrix of contacts   0-17   18-39   40-64   65+     Based on social contacts   0-17   16.76   4.34   3.59   0.46	infection fatality	18-39: 1.	0e-05				people are 95% less
vaccinated people     65+: 2.7e-03     Advise       Matrix of contacts     0-17     18-39     40-64     65+     Based on social contacts       0-17     16.76     4.34     3.59     0.46     surveys assessing	ratios (IFR) for	40-64: 2.	5e-04				probable of dying [35].
people     Image: Contracts     0-17     18-39     40-64     65+     Based on social contacts       contacts     0-17     16.76     4.34     3.59     0.46     surveys assessing	vaccinated	65+: 2.7€	e-03				
contacts 0-17 16.76 4.34 3.59 0.46 surveys assessing	people Matrix of		0 17	10 20	10 61	65 -	Based on social contacts
	contacts	0-17	16.76	4.34	3.59	0.46	surveys assessing

between age groups	18- 39	2.55	5 6.71	3.47	0.86	contacts in Greece [37]; these data were				
(0-17, 18-39,	40-	1.88	3 3.10	5.42	0.98	collected in the second				
40-64, 65+)	64 65+	0.41	1 1 32	1.67	1 4 1	nall of September 2020.				
Parameters related to vaccine efficacy and roll-out										
Vaccine efficacy	68%					52.4% - 92.6% [4,46].				
following the 1 <sup>st</sup>						[Assuming also reduction				
dose and before						in the probability of				
the 2 <sup>nd</sup> dose						acquiring infection]. This				
						days post-vaccination.				
Vaccine efficacy	95%					Vaccine efficacy in				
after the 2 <sup>nd</sup>						symptomatic infection				
dose						[4,47]. [Assuming				
						reduction in probability				
						efficacy is reached 14				
						days post-vaccination.				
Available doses	We assu	umed t	hat the nu	mber of dos	ses	· ·				
over time –	increase	ed duri	ng the firs	t quarter of	2021					
normal vaccine	from ap	proxim	nately 81,0	00 to 2.5 m	nillion					
(25/1/2021)	million i	ner duz	arter after	March 2021						
(23) 1/2021)	Estimat	es fron	n governm	ent stateme	ents on					
	<u>media a</u>	bout v	accine roll	out.						
	Period			Doses						
	12/202	0		81000						
	01/202	1		350000						
	02/202	1								
	03/202	1 1	•	2300000						
	03 202	<u> </u>		5300000						
	04 202	1		3700000						
Available doses	We assu	umed t	hat the nu	mber of dos	ses					
over time –	increase	ed duri	ng the firs	t quarter of	2021					
reduced Vaccine	from ap	proxim	hately 81,0	00 to 1 mil	lion and					
Availability (25/1/2021)	that it r	anged	Detween 4 arter after	March 2021	06.3					
(23/1/2021)	Estimat	es fron	n aovernm	ent stateme	ents on					
	media a	bout v	accine roll	out.						
	Period			Doses						
	12/202	0		81000						
	01/202	1		35000						
	02/202	1		10000						
	03/202	1		-800000						
	02 202	<u>-</u> 1		5300000						
	04 202	<u>-</u> 1		3700000						
Intention to aet	2,202	_	Durah	Deskuldul	Don't	Assessed in a sample of				
vaccinated (%)	Age	Tota	Probably/ Definitely	Probably/ Definitely	know/	1,097 adults [36]				
	group	1	Yes	No	Don't					
	18-	220	193	88	48	Ħ				
	39	329	(58.7)	(26.8)	(14.6)	Ц				
	40-	418	288	75	55					
	64	-	(68.9) 777	(17.9)	(13.2)	H				
	65+	350	(79.1)	(10.3)	(10.6)					

# **Supporting information C**

Baseline Scenario - Vaccine Availability -  $R_t$ =1.2

Cumulative	End of	End of June	End of	End of	End of
Deaths	March		August	October	December
0-17	6 (6-6)	14 (14-14)	15 (15-15)	16 (16-16)	17 (17-17)
18-39	75 (74-75)	143 (143-	146 (145-	146 (146-	146 (146-
		144)	146)	146)	146)
40-64	1854	3649 (3646-	3747 (3745-	3748	3749 (3747-
	(1846-	3652)	3749)	(3746-	3751)
	1863)			3750)	
65+	1897	2384 (2373-	2425 (2416-	2461	2495 (2485-
	(1886-	2393)	2436)	(2451-	2505)
	1906)			2471)	
Total deaths	3832	6190 (6176-	6333 (6321-	6371	6407 (6395-
	(3812-	6203)	6346)	(6359-	6419)
	3850)	-		6383)	-
Total life	73352.5	134837.5	138298.5	138654	138995.5
years lost	(72982-	(134670.5-	(138122-	(138524-	(138865.5-
	73685.5)	135044)	138435.5)	138784)	139125.5)

## S2 table. Cumulative number of deaths, when 0% of vaccines allocated to ages 18-74

### S3 Table. Cumulative number of deaths, when 20% of vaccines allocated to ages 18-74

Cumulative	End of	End of June	End of	End of	End of
deaths	March		August	October	December
0-17	6 (6-6)	14 (14-14)	15 (15-15)	16 (16-16)	17 (17-17)
18-39	75 (74-75)	139 (139-	141 (141-	141 (141-	141 (141-
		139)	141)	141)	141)
40-64	1852	3550 (3547-	3632	3634 (3631-	3635
	(1844-	3552)	(3630-	3635)	(3632-
	1859)		3634)		3636)
65+	1910	2498 (2488-	2542	2580 (2571-	2617
	(1900-	2506)	(2533-	2589)	(2609-
	1919)		2551)		2626)
Total deaths	3843	6201 (6188-	6330	6371 (6359-	6410
	(3824-	6211)	(6319-	6381)	(6399-
	3859)		6341)		6420)
Total life	73383.5	132451.5	135400	135799.5	136162
years lost	(73020-	(132291.5-	(135277-	(135646.5-	(136016-
	73656.5)	132567.5)	135523)	135892.5)	136255)

### S4 Table. Cumulative number of deaths, when 50% of vaccines allocated to ages 18-74

Cumulative	End of	End of June	End of	End of	End of
deaths	March		August	October	December
0-17	6 (6-6)	13 (13-13)	15 (15-15)	16 (16-16)	17 (17-17)
18-39	74 (74-75)	131 (131-	132 (132-	132 (132-	132 (132-
		132)	132)	132)	132)
40-64	1847	3366 (3363-	3419 (3417-	3422	3423 (3420-
	(1838-	3369)	3422)	(3419-	3425)
	1853)			3424)	
65+	1928	2723 (2713-	2772 (2762-	2816	2858 (2848-
	(1919-	2735)	2784)	(2806-	2869)
	1941)			2827)	

Total deaths	3855 (3837- 3875)	6233 (6220- 6249)	6338 (6326- 6353)	6386 (6373- 6399)	6430 (6417- 6443)
Total life	73306	128005	130138.5	130610	131007.5
years lost	(72973- 73630.5)	(127845- 128232.5)	(130008.5- 130312.5)	(130450- 130747)	(130847.5- 131144.5)

### S5 Table. Cumulative number of deaths, when 100% of vaccines allocated to ages 18-74

Cumulative	End of	End of June	End of	End of	End of
deaths	March		August	October	December
0-17	6 (6-6)	13 (13-13)	15 (15-15)	16 (16-16)	17 (17-17)
18-39	75 (74-75)	129 (129-	130 (130-	130 (130-	130 (130-
		130)	130)	130)	130)
40-64	1854	3304 (3300-	3311 (3307-	3313	3314 (3311-
	(1846-	3309)	3316)	(3310-	3319)
	1862)			3319)	
65+	1881	2278 (2268-	2312 (2302-	2340	2367 (2357-
	(1870-	2286)	2320)	(2330-	2375)
	1889)			2348)	
Total deaths	3816	5724 (5710-	5768 (5754-	5799	5828 (5815-
	(3796-	5738)	5781)	(5786-	5841)
	3832)			5813)	
Total life	73240.5	122923	123571.5	123901	124193.5
years lost	(72870-	(122733-	(123381.5-	(123741-	(124033.5-
	73536.5)	123182.5)	123777.5)	124137)	124399.5)

#### S6 Table. Cumulative number of infections, when 0% of vaccines allocated to ages 18-74

Cumulative	End of	End of June	End of	End of	End of
infections	March		August	October	December
0-17	205692	407403	449126	483022	514726
	(201056-	(395412-	(434390-	(465868-	(495223-
	210308)	419507)	464064)	500426)	534530)
18-39	355723	657034	675324	678502	681604
	(349647-	(642333-	(658976-	(661464-	(663874-
	361850)	671954)	691931)	695861)	699700)
40-64	354386	668880	695936	699982	703266
	(348331-	(654066-	(679082-	(682338-	(684908-
	360467)	683859)	713033)	717904)	721941)
65+	42180	57708	59220	60525	61809
	(40320-	(54237-	(55278-	(56142-	(56997-
	44094)	61357)	63394)	65195)	66971)

#### S7 Table. Cumulative number of infections, when 20% of vaccines allocated to ages 18-74

Cumulative	End of	End of June	End of	End of	End of
infections	March		August	October	December
0-17	205563	403485	445046	479322	511262
	(201024-	(391605-	(430414-	(462237-	(491857-
	210191)	415485)	459859)	496643)	531012)
18-39	355280	643554	662802	668244	671562
	(349268-	(628986-	(646528-	(651052-	(653659-
	361332)	658220)	679252)	685670)	689750)
40-64	353940	655699	682914	689238	693104
	(347968-	(641042-	(666185-	(671522-	(674617-
	360029)	670620)	699958)	707328)	712012)

65+	42170	58765	60310	61671	63013
	(40289-	(55217-	(56284-	(57194-	(58098-
	44097)	62461)	64541)	66410)	68248)

#### S8 Table. Cumulative number of infections, when 50% of vaccines allocated to ages 18-74

Cumulative	End of March	End of June	End of	End of	End of
0-17	205382	396362	437560	472510	504882
	(200846-	(384695-	(423185-	(455670-	(485694-
	210114)	408329)	452361)	489830)	524631)
18-39	354592	618118	638982	646856	650152
	(348511-	(603982-	(623014-	(629797-	(632378-
	360648)	632366)	655121)	664156)	668213)
40-64	353262	630735	658194	667522	671722
	(347216-	(616477-	(641843-	(649974-	(653378-
	359440)	645284)	674894)	685486)	690546)
65+	42128	60744	62360	63826	65248
	(40257-	(57067-	(58188-	(59184-	(60157-
	44041)	64557)	66723)	68701)	70642)

#### S9 Table. Cumulative number of infections, when 100% of vaccines allocated to ages 18-74

Cumulative	End of	End of June	End of	End of	End of
infections	March		August	October	December
0-17	205698	394808	434849	470048	502502
	(201113-	(383203-	(420571-	(453294-	(483371-
	210283)	406569)	449360)	487112)	521985)
18-39	355640	611915	638422	645310	648467
	(349658-	(598340-	(622750-	(628653-	(631115-
	361635)	625688)	654357)	662313)	666220)
40-64	354362	623402	651674	661004	664376
	(348317-	(609535-	(635668-	(643853-	(646514-
	360332)	637325)	667804)	678331)	682482)
65+	42111	59390	61865	63053	64212
	(40235-	(55683-	(57562-	(58343-	(59091-
	44022)	63234)	66355)	68022)	69658)